[go: up one dir, main page]

Ogata et al., 1997 - Google Patents

Absence of measles virus receptor (CD46) in lesions of subacute sclerosing panencephalitis brains

Ogata et al., 1997

Document ID
11173858622278589615
Author
Ogata A
Czub S
Ogata S
Cosby S
McQuaid S
Budka H
ter Meulen V
Schneider-Schaulies J
Publication year
Publication venue
Acta neuropathologica

External Links

Snippet

In this study we investigated pathological changes of the expression of the measles virus (MV) receptor, CD46, in subacute sclerosing panencephalitis (SSPE) brains. We analyzed CD46 expression in lesions of brain specimens from five SSPE patients in comparison to …
Continue reading at link.springer.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature

Similar Documents

Publication Publication Date Title
US7371833B1 (en) Nucleic acid molecules with specific recognition of native PrPSc, production and use
JP2024012385A (en) ALS-related diamino acid repeat-containing protein
US9879257B2 (en) Modulators of alpha-synuclein toxicity
US8741868B2 (en) Pharmaceutical composition including an HIF-2 alpha inhibitor as an active ingredient for preventing or treating arthritis
JP2006526992A (en) Methods for detecting cancer and monitoring cancer progression
US20060160087A1 (en) Monitoring and treatment of amyotrophic lateral sclerosis
JP2012067109A (en) MODULATOR OF α-SYNUCLEIN TOXICITY
Ogata et al. Absence of measles virus receptor (CD46) in lesions of subacute sclerosing panencephalitis brains
Yang et al. Kruppel-like factor 10 protects against acute viral myocarditis by negatively regulating cardiac MCP-1 expression
JPH08509808A (en) Neurofilament protein gene expression and detection of Alzheimer's disease
US20020155513A1 (en) Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
SK15032001A3 (en) A method for determining marker protein expression for diagnosing preclinical or clinical transmissible spongiform encephalopathies, a test kit and its use, and the use of antibody and oligonucleotides
Itzhaki Possible factors in the etiology of Alzheimer's disease
JP2019158753A (en) Biomarkers for lymphangioleiomyomatosis
Ogata et al. Expression of the interferon-α/β-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis
KR102443101B1 (en) Biomarker composition for predicting the risk of developing neurodevelopmental disorders
WO2023101599A2 (en) A method of sorting a heterogenous macrophage population
KR102077229B1 (en) Composition for preventing or treating neurodegenerative disease comprising inducer or activator of nSMase2
Kong et al. Neurotoxicity of cerebro-spinal fluid from patients with Parkinson’s disease on mesencephalic primary cultures as an in vitro model of dopaminergic neurons
US20040157225A1 (en) Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders
KR102034929B1 (en) Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising NCKAP1 protein or gene thereof
JP6721571B2 (en) Use of 15 male reproductive proteins or combinations thereof
KR102615797B1 (en) Method for predicting the efficacy of treatment effects in glioblastoma by T cells
KR101039996B1 (en) Genes that control differentiation from hematopoietic stem cells to megakaryocytes and platelets and uses thereof
Hosokawa et al. Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs